Clarence Joustra, DO
Family Medicine · Lamar, MONPI 1942202080
Payments from drug & device makers
Across 104 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$414
- Pfizer$319
- AbbVie$284
- Lundbeck LLC$199
- Otsuka America Pharmaceutical, Inc.$172
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$84
- plus $302 from 14 others
What the payments were for
- Food & beverage$1,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $414 |
| Pfizer | 16 | $319 |
| AbbVie(2 entities) | 30 | $284 |
| Lundbeck LLC | 8 | $199 |
| Otsuka America Pharmaceutical, Inc. | 8 | $172 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| Ardelyx, Inc. | 3 | $50 |
| Indivior Inc. | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Verona Pharma, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Dexcom, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$1,776 in reported general payments places this provider in the 70th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 302 | $134,888 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $90,345 |
| RexultiBrexpiprazole | 89 | $69,341 |
| MyrbetriqMirabegron | 140 | $61,396 |
| OzempicSemaglutide | 48 | $52,186 |
| JardianceEmpagliflozin | 55 | $45,523 |
| RybelsusSemaglutide | 34 | $45,070 |
| PerserisRisperidone | 13 | $39,846 |
| LinzessLinaclotide | 54 | $38,832 |
| JanuviaSitagliptin Phosphate | 35 | $37,865 |
| Invega SustennaPaliperidone Palmitate | 14 | $34,532 |
| VraylarCariprazine Hcl | 41 | $34,477 |
| XareltoRivaroxaban | 49 | $33,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $28,225 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $19,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $319 | $140,568320 claims |
| AbbVieLinzess, Vraylar, Creon, Savella, Lumigan | $284 | $99,496146 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $15 | $99,428108 claims |
| Novo NordiskOzempic, Rybelsus | $14 | $97,25782 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $172 | $69,34189 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $12 | $67,97563 claims |
| Indivior Inc.Perseris | $38 | $39,84613 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $414 | $16,02326 claims |
| UCB, Inc.Vimpat | $15 | $14,38315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Lamar
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.